These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 34283019

  • 1. Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy.
    Rosenberg R, Thorpy MJ, Dauvilliers Y, Schweitzer PK, Zammit G, Gotfried M, Bujanover S, Scheckner B, Malhotra A.
    J Clin Sleep Med; 2022 Jan 01; 18(1):235-244. PubMed ID: 34283019
    [Abstract] [Full Text] [Related]

  • 2. Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
    Weaver TE, Pepin JL, Schwab R, Shapiro C, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo PJ, Mayer G, Sarmiento K, Baladi M, Bron M, Chandler P, Lee L, Malhotra A.
    J Clin Sleep Med; 2021 Oct 01; 17(10):1995-2007. PubMed ID: 34606437
    [Abstract] [Full Text] [Related]

  • 3. Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea.
    Rosenberg R, Baladi M, Bron M.
    J Clin Sleep Med; 2021 Apr 01; 17(4):711-717. PubMed ID: 33226332
    [Abstract] [Full Text] [Related]

  • 4. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea.
    Malhotra A, Shapiro C, Pepin JL, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo PJ, Mayer G, Sarmiento K, Baladi M, Chandler P, Lee L, Schwab R.
    Sleep; 2020 Feb 13; 43(2):. PubMed ID: 31691827
    [Abstract] [Full Text] [Related]

  • 5. Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy.
    Schweitzer PK, Strohl KP, Mayer G, Rosenberg R, Chandler P, Baladi M, Lee L, Malhotra A.
    J Clin Sleep Med; 2021 Apr 01; 17(4):659-668. PubMed ID: 33179591
    [Abstract] [Full Text] [Related]

  • 6. Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy.
    Emsellem HA, Thorpy MJ, Lammers GJ, Shapiro CM, Mayer G, Plazzi G, Chen D, Carter LP, Villa KF, Lee L, Menno D, Black J, Dauvilliers Y.
    Sleep Med; 2020 Mar 01; 67():128-136. PubMed ID: 31926465
    [Abstract] [Full Text] [Related]

  • 7. Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression.
    Krystal AD, Benca RM, Rosenberg R, Schweitzer PK, Malhotra A, Babson K, Lee L, Bujanover S, Strohl KP.
    J Psychiatr Res; 2022 Nov 01; 155():202-210. PubMed ID: 36070638
    [Abstract] [Full Text] [Related]

  • 8. Solriamfetol: A Review in Excessive Daytime Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnoea.
    Hoy SM.
    CNS Drugs; 2023 Nov 01; 37(11):1009-1020. PubMed ID: 37847434
    [Abstract] [Full Text] [Related]

  • 9. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial.
    Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, Wang H, Lu Y, Black J, Malhotra A, Strohl KP, TONES 3 Study Investigators.
    Am J Respir Crit Care Med; 2019 Jun 01; 199(11):1421-1431. PubMed ID: 30521757
    [Abstract] [Full Text] [Related]

  • 10. Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment.
    Schweitzer PK, Mayer G, Rosenberg R, Malhotra A, Zammit GK, Gotfried M, Chandler P, Baladi M, Strohl KP.
    Chest; 2021 Jul 01; 160(1):307-318. PubMed ID: 33631141
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials.
    Subedi R, Singh R, Thakur RK, K C B, Jha D, Ray BK.
    Sleep Med; 2020 Nov 01; 75():510-521. PubMed ID: 33032062
    [Abstract] [Full Text] [Related]

  • 12. Solriamfetol for the Management of Excessive Daytime Sleepiness.
    Cuomo MC, Sheehan AH, Jordan JK.
    J Pharm Pract; 2022 Dec 01; 35(6):963-970. PubMed ID: 33882756
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of solriamfetol for excessive sleepiness in narcolepsy and obstructive sleep apnea: findings from randomized controlled trials.
    Wang J, Yang S, Li X, Wang T, Xu Z, Xu X, Gao H, Chen G.
    Sleep Med; 2021 Mar 01; 79():40-47. PubMed ID: 33472129
    [Abstract] [Full Text] [Related]

  • 14. Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial.
    Weaver TE, Drake CL, Benes H, Stern T, Maynard J, Thein SG, Andry JM, Hudson JD, Chen D, Carter LP, Bron M, Lee L, Black J, Bogan RK.
    Ann Am Thorac Soc; 2020 Aug 01; 17(8):998-1007. PubMed ID: 32353246
    [Abstract] [Full Text] [Related]

  • 15. Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study.
    Strollo PJ, Hedner J, Collop N, Lorch DG, Chen D, Carter LP, Lu Y, Lee L, Black J, Pépin JL, Redline S, Tones 4 Study Investigators.
    Chest; 2019 Feb 01; 155(2):364-374. PubMed ID: 30471270
    [Abstract] [Full Text] [Related]

  • 16. Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea.
    Powell J, Piszczatoski C, Garland S.
    Ann Pharmacother; 2020 Oct 01; 54(10):1016-1020. PubMed ID: 32270686
    [Abstract] [Full Text] [Related]

  • 17. Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea.
    Ronnebaum S, Bron M, Patel D, Menno D, Bujanover S, Kratochvil D, Lucas E, Stepnowsky C.
    J Clin Sleep Med; 2021 Dec 01; 17(12):2543-2555. PubMed ID: 34402784
    [Abstract] [Full Text] [Related]

  • 18. Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial.
    Dauvilliers Y, Shapiro C, Mayer G, Lammers GJ, Emsellem H, Plazzi G, Chen D, Carter LP, Lee L, Black J, Thorpy MJ.
    CNS Drugs; 2020 Jul 01; 34(7):773-784. PubMed ID: 32588401
    [Abstract] [Full Text] [Related]

  • 19. Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy.
    Malhotra A, Strollo PJ, Pepin JL, Schweitzer P, Lammers GJ, Hedner J, Redline S, Chen D, Chandler P, Bujanover S, Strohl K.
    Sleep Med; 2022 Dec 01; 100():165-173. PubMed ID: 36084494
    [Abstract] [Full Text] [Related]

  • 20. A randomized study of solriamfetol for excessive sleepiness in narcolepsy.
    Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, Chen D, Carter LP, Wang H, Lu Y, Black J, Dauvilliers Y.
    Ann Neurol; 2019 Mar 01; 85(3):359-370. PubMed ID: 30694576
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.